How to Cope With Stress When You Have Myasthenia Gravis

Immunosuppressive Therapy Tied to More COVID-19 Hospitalization Risk

People with myasthenia gravis (MG) who are receiving immunosuppressive therapy are more likely to be hospitalized for a COVID-19 infection, yet the majority of patients are discharged without any complications, a single center study reports. “Immunosuppressive therapy was continued during COVID-19 infection,” and “most of hospitalized patients were discharged…

Findings in UCB’s Myasthenia Gravis Pivotal Trials Detailed

Two investigational UCB treatments for generalized myasthenia gravis (gMG) — zilucoplan and rozanolixizumab — continue to show benefits in gMG patients, according to recently reported findings from Phase 3 trials. Both delivered as subcutaneous (under-the-skin) injections, zilucoplan works by blocking an immune system protein called C5 that…

How to Decide Whether a Service Dog Is Right for You

“My pet Fido makes me feel so much better. Where can I get him a service dog vest?” You can’t. Well, you can, but unless Fido is specifically trained to perform tasks related to your disability, you shouldn’t. And I’ll tell you why. I’ve had two trained service dogs since…

Ultomiris Approved in Europe for Adults With AChR-positive gMG

The European Commission has approved Ultomiris (ravulizumab) as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG). Eligible patients will be positive for antibodies targeting the acetylcholine receptor (AChR) — the most common type of MG-causing antibody. Ultomiris is now the first long-acting C5 complement…

I’m More Than the Labels That Come With Myasthenia Gravis

The caregiver. The parent. The big sister. The only child. The husband/wife/spouse. The honors student. The executive. The jock. The soldier. The patient. The flaky friend. The chronically ill. These are all titles and roles that society establishes for us, or we establish ourselves. We might be proud to…

FDA Approval Sought for Under-the-skin Efgartigimod for gMG

Argenx has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of subcutaneous efgartigimod — an under-the-skin formulation of the active agent in Vyvgart — for the treatment of generalized myasthenia gravis (gMG). FDA approval would provide gMG patients with an additional delivery…